Health Spending Expected To Outpace Growth In The Overall Economy

A recent report from the Centers for Medicare and Medicaid Services (CMS) shows that per capita health spending slowed in 2021. The growth rate was 2.6% down from 9.9% in 2020, after a ramp-up that year due to the COVID-19 pandemic.

As utilization returns to pre-pandemic levels and price inflation in the health sector abates somewhat, per person health spending is projected to rebound to an annual rate of 4.8% per capita from 2022 to 2031, which is slightly above pre-pandemic growth rates, which averaged to 3.9% from 2014 to 2019.

Prescription drug spending grew 7.7% per capita from 2020 to 2021. Increases in Medicaid prescription drug spending drove overall per capita prescription drug spending growth during the pandemic, largely due to increases in Medicaid enrollment. However, in 2022, slower Medicaid enrollment growth is expected to have slowed growth to 4.7% per capita. Growth in drug spending is projected to slow to 2.8% per capita in 2023, as Medicaid enrolment declines

Medicare prescription drug spending is also expected to slow as generic drugs enter the market for some drug categories and Inflation Reduction Act Medicare drug price reforms take effect.

With care resuming after the first year of the pandemic, out-of-pocket spending per capita also rebounded – rising by 10.3% in 2021 from 2020. Out-of-pocket spending per person declined from $1,229 in 2019 to $1,192 in 2020, followed by a rebound to $1,315 in 2021. CMS actuaries expect growth in per capita out-of-pocket spending to moderate in coming years. Out-of-pocket spending is expected to have grown by 3.8% per capita in 2022 and 4.4% per capita in 2023, but to drop to an average of 3.4% per capita for the following seven years.

Across all payers, per enrollee spending is projected to accelerate in 2023 and 2024. Growth in per enrollee Medicare spending is estimated to have slowed in 2022 to 3.1%, but is expected to rebound in 2023, partly driven by return in hospital use after a decrease in 2022. Per enrollee Medicaid spending is expected to grow by 7.4% in 2024, the highest rate in 30 years.

In the years leading up to the pandemic, the share of gross domestic product (GDP) constituting health care hovered around 17.6%. In 2020, when health spending surged as the overall economy slowed, this share climbed to 19.7% of GDP. In 2021, health expenditures as a share of GDP fell to 18.3% as health spending grew much slower than GDP. Health spending is estimated to have grown more slowly than the economy in 2022 and is estimated to have returned to pre-pandemic levels (17.4% of GDP). However, health spending growth is expected to outpace growth in the overall economy starting in 2023 and eventually hit 19.6% of GDP by 2031.

 

Source Link

Recommended Articles

CMS Finalizes Major Changes To ACA Exchanges, Including Greater Access To Catastrophic Plans

Editor’s Note: Covered California is a State-Based Marketplace (SBM). For details on how these new rules will impact Covered California and other SBMs we recommend the following Princeton University linked report: (Broker rule changes appear at the bottom of the Princeton analysis.) https://shvs.org/wp-content/uploads/2025/06/SHVS_2025-Final-Marketplace-Integrity-Rule.pdf.   The Trump administration on Friday finalized a major rule reshaping the ...

Read More

Eroding ACA Enrollment Portends Higher Insurance Rates

Enrollment in the Affordable Care Act continues to erode as some customers struggle to make premium payments, with the declining numbers churning market uncertainty for insurers. In response, insurers are likely to raise rates again next year, following this year’s larger-than-typical hikes. Sign-ups were already down in January by about 1.2 million from last year’s record enrollment. For ...

Read More

White House Adds Generic Drugs To Direct-To-Consumer TrumpRx Site

The Trump administration on Monday said it is adding generic medications to its direct-to-consumer drug sales website, TrumpRx, in a bid to expand a platform that is key to his administration’s efforts to lower prescription drug costs in the U.S. The administration is adding more than 600 generic drugs to the site, President Donald Trump said at an event ...

Read More

Supreme Court Rejects Big Pharma Appeals Challenging Negotiated Drug Prices In Medicare

The US Supreme Court on Monday rejected a series of appeals from several of the nation’s largest drugmakers challenging a program that is expected to save taxpayers and the federal government billions of dollars by requiring the companies to negotiate with Medicare on the prices for some of their most popular drugs. The court’s decision to deny ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square